Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PRKCA | P17252 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20414057 | 0.82 | PRKCA (0.44) | POLBGAANPSR1PRKCA | |
| SCHEMBL19523497 | 0.80 | ALDH1A1 (0.43) | GAAHTR1ADRD2HTR2AHTR7 | |
| SCHEMBL6314938 | 0.80 | GAA (0.41) | POLBGAANPSR1PRKCANPC1 | |
| SCHEMBL25456607 | 0.79 | PRKCA (0.39) | POLBGAANPSR1PRKCA | |
| SCHEMBL4698870 | 0.78 | LMNA (0.43) | HTR1ADRD2HTR2AHTR7NPC1 | |
| SCHEMBL18665330 | 0.78 | POLB (0.40) | POLBGAANPSR1PRKCA | |
| SCHEMBL4258156 | 0.78 | POLB (0.48) | POLBGAANPSR1PRKCANPC1 | |
| SCHEMBL863336 | 0.77 | NAAA (0.45) | GAAHTR1ADRD2HTR2AHTR7 | |
| SCHEMBL17451509 | 0.75 | PRKCA (0.43) | POLBGAANPSR1PRKCA | |
| SCHEMBL16272977 | 0.75 | HTR1A (0.31) | HTR1ADRD2HTR2AHTR7NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024494-A1 | SMALL-MOLECULE CONJUGATE AND USE THEREOF | ANHUI CHINA RESOURCES JINCHAN PHARMACEUTICAL CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-8299266-B2 | Processes for making epothilone compounds and analogs | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120178941-A1 | PROCESSES FOR MAKING EPOTHILONE COMPOUNDS AND ANALOGS | BRISTOL-MYERS SQUIBB COMPANY | 2012-07-12 | — | — | US | disclosed |
| US-8143415-B2 | Processes for making epothilone compounds and analogs | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-RE42930-E1 | Aziridinyl-epothilone compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-15 | — | — | US | disclosed |
| US-7872145-B2 | 7,11-dihydroxy-17-(2-hydroxyethyl)-8,8,10,12-tetramethyl-3-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)-4-oxa-17-azabicyclo[14.1.0]heptadecane-5,9-dione; anticarcinogenic agent; antiproliferative agent; low toxicity ( side effects reduction) | Bristol-Mysers Squibb Company (US) | 2011-01-18 | — | — | US | disclosed |
| US-20100324302-A1 | PROCESSES FOR MAKING EPOTHILONE COMPOUNDS AND ANALOGS | BRISTOL-MYERS SQUIBB COMPANY | 2010-12-23 | — | — | US | disclosed |
| US-20070276018-A1 | AZIRIDINYL-EPOTHILONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275904-A1 | CONJUGATES OF AZIRIDINYL-EPOTHILONE ANALOGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276018-A1 | AZIRIDINYL-EPOTHILONE COMPOUNDS | CBR3, CBR1, NR0B1 | POLB 3616/4885GAA 4767/4885NPSR1 68/4885 |
| US-20100324302-A1 | PROCESSES FOR MAKING EPOTHILONE COMPOUNDS AND ANALOGS | DHPS, EPOR, SQLE | POLB 965/4885GAA 2300/4885NPSR1 1661/4885 |
| US-20070275904-A1 | CONJUGATES OF AZIRIDINYL-EPOTHILONE ANALOGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | FOLR1, FOLR2, DHFR | POLB 3176/4885GAA 2529/4885NPSR1 212/4885 |
| US-20120178941-A1 | PROCESSES FOR MAKING EPOTHILONE COMPOUNDS AND ANALOGS | EPOR, PYCR1, AZI2 | POLB 2566/4885GAA 3651/4885NPSR1 2227/4885 |
| US-20240024494-A1 | SMALL-MOLECULE CONJUGATE AND USE THEREOF | SLC7A5, SLC43A1, CD44 | POLB 3003/4885GAA 385/4885NPSR1 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.